A 15-year-old male orally consumed an unknown but fatal amount of sustained release hydromorphone. He was naïve to opioid use. No other drugs or alcohol were involved. The cause of death was acute aspiration-related bronchopneumonia, secondary to hydromorphone ingestion; the manner of death was accidental. Hydromorphone and hydromorphone-3-glucuronide were quantified in postmortem fluids by tandem liquid chromatography-mass spectrometry. The hydromorphone concentrations in the peripheral blood, urine, and vitreous humor were 57, 4460, and 31 ng/mL, respectively. The hydromorphone-3-glucuronide concentrations in the corresponding three fluids were 459, 36,400, and 40 ng/mL. Hydromorphone-3-glucuronide accumulation probably did not contribute significantly to the opiate toxicity. The proposed minimum lethal hydromorphone blood concentration in the nontolerant user is in the vicinity of 60 ng/mL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1556-4029.2010.01618.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Repurposing prescribed hydromorphone: Alternative uses of safer supply and tablet-injectable opioid agonist treatment to meet unaddressed health needs.
Int J Drug Policy
November 2024
British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC, V6Z 2A9, Canada; Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada; School of Public Health Sciences, Faculty of Health, University of Waterloo, 200 University Avenue West, Waterloo ON, N2L 3G1, Canada. Electronic address:
Article Synopsis
- In Canada, opioid agonist treatment programs provide hydromorphone to people at high risk of overdose, with varying methods for dispensing it, aimed at reducing reliance on contaminated drugs.
- A qualitative study involving in-depth interviews explored how individuals repurpose hydromorphone tablets to meet various personal needs beyond just treating addiction.
- Findings reveal that while many participants reduced their use of illicit drugs, they also used hydromorphone for managing anxiety, sleep issues, withdrawal symptoms, and chronic pain, highlighting its role in addressing unmet health needs in a public health context.
Access to tablet injectable opioid agonist therapy in rural and smaller urban settings in British Columbia, Canada: a qualitative study.
Subst Abuse Treat Prev Policy
March 2023
British Columbia Centre On Substance Use, 400-1045 Howe Street, Vancouver, BC, V6Z 2A9, Canada.
Background: Rural and smaller urban settings in Canada are disproportionately impacted by the overdose crisis, highlighting the need for novel public health interventions within these jurisdictions. Tablet injectable opioid agonist therapy (TiOAT) programs have been implemented in select rural communities as a means to address drug-related harms. However, little is known about the accessibility of these novel programs.
View Article and Find Full Text PDFLong-Term Dexmedetomidine Use and Safety Profile in Palliative Care: A Case Report.
J Palliat Med
June 2023
Division of Palliative Medicine, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland.
There is a lack of report of conscious sedation used as a last resort therapy for alleviating severe symptoms. To achieve this goal, dexmedetomidine appears to be a promising option. We report a case of successful two-month long treatment of intravenous (IV) dexmedetomidine added to hydromorphone for intractable cancer pain, restlessness, severe sleep disorder, anxiety, and craving symptoms in a 40-year-old man with active polysubstance use, receiving escalating doses of opioids for intractable abdominal cancer pain together with benzodiazepines.
View Article and Find Full Text PDFPain behaviors before and after treatment of oral disease in cats using video assessment: a prospective, blinded, randomized clinical trial.
BMC Vet Res
April 2020
Department of Clinical Sciences, Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, QC, J2S 2M2, Canada.
Background: Specific behaviors associated with pain in cats with oral disease have not been consistently studied. The aim of this exploratory study was to identify pain-induced behaviors in cats before and after treatment of oral disease using video assessment. Twenty-four cats (6 ± 3.
View Article and Find Full Text PDFThe impact of the prescription opioid epidemic on young children: Trends and mortality.
Drug Alcohol Depend
June 2020
Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, United States.
Background: Our objective was to describe trends and deaths in young children associated with opioid analgesics.
Methods: Analysis of pediatric exposures using the RADARS System Poison Center Program from July 1, 2010 through December 31, 2018. Cases involving a child < 6 years, with an exposure to one or more opioids: buprenorphine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tramadol.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!